FDA, AAMI Explore How To Consider Benefits, Risks In Postmarket
This article was originally published in The Gray Sheet
Executive Summary
FDA has already put a lot of work into mapping out pathways for weighing benefit versus risk in premarket review decisions. Now the agency, with the help of the Association for the Advancement of Medical Instrumentation and industry, is trying to provide the same support for compliance and enforcement decisions.
You may also be interested in...
Assessing Patient Impact From Recalls Often A Judgment Call, US FDA Says
Industry participants on an FDA-convened webinar asked for further guidance on how to evaluate the effects enforcement actions might have on patients and the public health. The webinar was organized to discuss a recent FDA draft guidance on benefit-risk considerations for post-market decisions.
Industry, FDA Coming Together On Risk Management For Marketed Devices
Representatives from the device industry and FDA are trying to establish common ground for how to assess and manage risk of potential safety or compliance issues that crop up for marketed devices.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.